Ovarian cancer. Experimental chemotherapy.
Ovarian cancer is a drug-sensitive disease, yet most patients still succumb after initial response. Experimental approaches to this disease include the discovery of new drugs, including taxol and ifosfamide; evaluation of candidate drugs such as tetraplatin and topotecan; and approaches to overcome intrinsic and/or acquired resistance. The latter has been addressed by increasing dose-intensity of currently available therapy, developing agents to abrogate dose-limiting toxicity, and by attempts to interfere with mechanisms of resistance.
McGuire
W P
WP
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy*